For Healthcare Professionals

Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer


About the study

150 adults patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy will enter in the trial. Patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will be stratified by number of prior VEGFR targeted therapy (1versus2) and prior lenvatinib treatment (yes versus no)

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Signed informed consent must be obtained prior to performing any specific pre-screening and screening procedure
  2. Male or female >= 18 years of age at the time of informed consent
  3. Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid cancer
  4. Radio active iodine refractory disease
  5. BRAFV600E mutation positive tumor sample as per Novartis designated central laboratory result
  6. Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapy
  7. Eastern Cooperative Oncology Group performance status >= 2
  8. At least one measurable lesion as defined by RECIST 1.1


Exclusion Criteria:

  1. Anaplastic or medullary carcinoma of the Tyroid
  2. Previous treatment with BRAF inhibitor and/or MEK inhibitor
  3. Concomitant RET Fusion Positive Thyroid cancer
  4. Receipt of any type of small molecule kinase inhibitor within 2 weeks before randomization
  5. Receipt of any type of cancer antibody or systemic chemotherapy within 4 weeks before randomization
  6. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
  7. A history or current evidence/risk of retinal vein occlusion or central serous retinopathy
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-888-669-6682Email iconEmail Study Center

Study’s details


Differentiated Thyroid Cancer

Age (in years)



Phase 3

Participants needed


Est. Completion Date

Oct 30, 2026

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.